Aandeel A195940 HK INNO.N CORPORATION
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen HK inno.N Corporation

Aandelen

A195940

KR7195940002

slotkoers Korea S.E.
Andere beurzen
 00:00:00 17-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
34.550 KRW 0,00% Intraday-grafiek van HK inno.N Corporation -2,95% -22,27%
2022 Sebela Pharmaceuticals® verwerft exclusieve licentierechten van HK inno.N Corporation voor de ontwikkeling en commercialisering van Tegoprazan in de VS en Canada. CI
2022 Sebela Pharmaceuticals gaat een exclusief partnerschap aan met HK inno.N Corporation CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada
Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.
HK inno.N Corporation's Equity Buyback announced on February 9, 2022, has expired with 574,608 shares, representing 1.99% for KRW 24,180.98 million.
Indian Indices Close in the Red Midweek; Shree Cement Slides 4%
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.
Dr. Reddy's to Market HK inno.N's Gastrointestinal Diseases Drug in India, Emerging Markets
Dr. Reddy's Laboratories Ltd. Enters into an Exclusive Partnership with South Korea-Based HK Inno.N Corporation
HK inno.N's Gastroesophageal Reflux Disease Drug Gets Marketing Approval in China
Y-Biologics Inc. announced that it expects to receive KRW 30 billion in funding from a group of investors
HK inno.N Corporation announces an Equity Buyback for KRW 24,200 million worth of its shares.
HK inno.N Corporation authorizes a Buyback Plan.
Kolmar Korea to Acquire 40% Stake in Biotech Firm Next & Bio
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021
HK inno.N Enters License Agreement for Gastroesophageal Reflux Drug in the US
HK inno.N Corporation(KOSDAQ:A195940) added to S&P Global BMI Index
HK inno.N Corporation has completed an IPO in the amount of KRW 596.903 billion.
HK inno.N Corporation has filed an IPO.
HK inno.N Corporation announced that it has received KRW 49.9999765 billion in funding from Kolmar Korea Co., Ltd.
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers A195940
  4. Nieuws HK inno.N Corporation
  5. Andere talen